Press Releases and Blog
Fact: Employers are under no obligation to hire pharmacy benefit companies, but a vast majority of employers work with pharmacy benefit companies. Recent findings from
In case you missed it, the Pharmaceutical Care Management Association (PCMA) released a new Rx Research Corner blog, by Vice President of Research Amanda Frost,
In case you missed it, Katie Payne, senior vice president for strategic communications for the Pharmaceutical Care Management Association (PCMA), discusses how the BIO International
Webinar Highlights Big Pharma’s Rising Launch Prices and Cost-Saving Value of Pharmacy Benefit Companies
Last month, the IQVIA Institute held a webinar, “The Use of Medicines in the U.S. 2023.” Panelists highlighted how big drug companies set the price of
Economists Explain Policies Restricting Pharmacy Benefits Will Lead To Higher Costs, Less Competition, And Fewer Choices For Employers In case you missed it, Joe Grogan,
New Episode Of “The Pharmacy Benefit” Podcast Discusses Why We Need Competition To Drive Down Prescription Drug Costs
Alex Brill and Angela Banks Dive into the Critical Need for Competition, Big Drug Companies’ Abuse of the Patent System, and Biosimilar Adoption In case
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on a new white paper issued by the Institute
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today released a new report, “Drug Manufacturer Strategies for Keeping Drug Costs High,” on pharmaceutical industry pricing tactics
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on Congress’ passage of the Bipartisan Infrastructure Package:
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on Congress’ agreement on drug pricing language for the
(Washington, D.C.) — Pharmaceutical Care Management Association President and CEO JC Scott issued the following statement on the House Judiciary Committee’s markup of H.R. 2883,
(Washington, D.C.) — Recently, the Pharmaceutical Care Management Association (PCMA) announced Dr. William Fleming, President of Pharmacy Solutions and Chief Corporate Affairs Officer at Humana Inc.,
Pharmaceutical Care Management Association, the leading PBM trade group, claimed the number of independent pharmacies has actually grown. “Over the last 10 years, the number of U.S. independent pharmacies has increased by nearly 2,000 stores of 8%,” PCMA said in a written statement to the Washington Examiner. “That represents a stable — if not growing — market for independent pharmacies in this country. A healthy independent pharmacy market and strong partnership with PBMs helps to lower prescription drug costs, create competition, coordinate better care, reduce medication errors, and increase medication adherence — all of which is squarely in the interest of pharmacies, patients, and the health care system.”
The Pharmaceutical Care Management Association, which represents pharmacy benefit managers, said commercial insulin copays currently average $23.
Blaming healthcare costs on PBMs is tempting, but misguided. Both the Trump and Biden administrations have bludgeoned the industry, because it seems like the simple way to cut the Gordian knot of American medicine in half. But it’s not: Without PBMs, prescription drugs would cost patients and the government even more.
“There’s this narrative out there, this assumption, that community pharmacies are closing and they’re closing in escalating rates,” PCMA President and CEO JC Scott said
The market for prescription drugs is exceedingly complicated, in part because there are many disparate actors…
Washington is a town not known for bipartisan agreement. But its swarms of drug-company lobbyists appear to have united both parties in opposition to pharmacy
Crain’s Detroit Business: FTC should examine the real factors leading to high prescription drug costs
In my experience, PBMs do not contribute to the rising costs of prescription drugs—in fact, they do the exact opposite.
“The PBM industry is the only stakeholder in the chain dedicated to seeking lower costs, and we are proud to play that role,” said JC Scott, president and CEO of the Pharmaceutical Care Management Association. “PBMs do that work for the employer, union health plan, and government clients who hire them and most importantly, the patients for whom those plans provide coverage.”